Indications and Important Safety Information
Indications: Hyalgan® and Hymovis® are indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and to simple analgesics (e.g. acetaminophen).
Important Safety Information: Hyalgan® and Hymovis® are contraindicated in patients with known hypersensitivity to hyaluronate preparations or gram positive bacterial proteins (Hymovis® only) or patients with infections/skin diseases in the area of the injection site/joint. The safety and effectiveness of Hymovis® has not been tested in pregnant women, nursing mothers or children. See package insert for full prescribing information including adverse events, warnings, precautions, and side effects at www.Hyalgan.com and www.Hymovis.com. Rx Only
Indication
HYMOVIS® is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy or simple analgesics (e.g., acetaminophen).
Important Safety Information
HYMOVIS® is contraindicated in patients with known hypersensitivity (allergy) to hyaluronate preparations or gram-positive bacterial proteins. Do not administer HYMOVIS® to patients with infections or skin diseases in the area of the injection site or joint.
The safety and effectiveness of the use of HYMOVIS® have not been tested in pregnant women, nursing mothers, or children. The safety and effectiveness of the use of HYMOVIS® in joints other than the knee, or for use concomitantly with other intra-articular (IA) injections, have not been established. The effectiveness of repeat treatment cycles of HYMOVIS® has not been established.
Arthralgia, transient pain, or swelling may occur after the IA injection. The incidence of arthralgia in the clinical study for HYMOVIS® was equivalent to the control group. No serious adverse events or pseudoseptic reactions were reported. Transient increases in inflammation following any IA hyaluronan injection have been reported in some patients with inflammatory joint conditions.
Strict aseptic technique should be used by licensed medical professionals trained to deliver agents into the knee joint. Joint effusion should be removed prior to injection of HYMOVIS®. Do not use disinfectants containing quaternary ammonium salts for skin preparation as hyaluronan can precipitate in their presence.
Patients should avoid strenuous or prolonged (eg, more than one hour) physical activities within 48 hours following the IA injection.
Please see Prescribing Information.
RX Only.
We could not match a prescriber with the information provided. Please select ‘OK’ to review your entry and try again.
For additional support please contact 866-Hymovis
One or more of the authentication questions were answered incorrectly.
The Prescriber has been found; checking status now.
You have not successfully completed the authentication process
For additional support please contact 866-Hymovis.
Congratulations! You have successfully completed the verification process.
The prescriber will be validated until 4/19/2025 6:29:21 AM